%PDF-1.4
%
56 0 obj
<>
endobj
53 0 obj
<>
endobj
105 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-06T10:02:29Z
2024-03-28T19:01:25-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T19:01:25-07:00
application/pdf
Heather
2003-821.marchsupl.69
uuid:2d8baf61-1dd2-11b2-0a00-0309275d6100
uuid:2d8baf63-1dd2-11b2-0a00-aa0000000000
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
57 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
123 0 obj
[127 0 R]
endobj
124 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2004, V)110.7 (olume 31, Supplement 69)]TJ
0 Tc 0 Tw -37.5268 -0.0313 Td
(34)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(ACKNOWLEDGMENT)Tj
/T1_3 1 Tf
0.2924 Tw 8 0 0 8 54 703.1616 Tm
[(I would like to thank )54.9 (Alan Silman, my co-principal investigator and)]TJ
0.0387 Tw 0 -1.25 TD
[(Marwan Bukhari, Graham Dunn, Beverley Harrison, and Nicola )17.7 (W)39.8 (iles for)]TJ
0.0497 Tw T*
(valuable discussions about these methodological issues and their potenti\
al)Tj
0.0554 Tw T*
[(solutions. )17.7 (W)79.9 (e are grateful to the general practitioners and rheumatologists)]TJ
0.02499 Tw T*
(in the Norwich area for continuing to refer patients to and support NOAR\
.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 54 639.1616 Tm
(REFERENCES)Tj
/T1_3 1 Tf
0.02499 Tw 8 0 0 8 61 629.1616 Tm
[(1.)-875.1 (Symmons DPM, Barrett EM, Bankhead CR, Scott DGI, Silman )54.8 (AJ.)]TJ
1.675 -1.25 Td
(The incidence of rheumatoid arthritis in the United Kingdom:)Tj
T*
[(results from the Norfolk )54.8 (Arthritis Register)54.8 (. Br J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;33:735-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Silman )54.8 (AJ, Symmons DPM. Reporting requirements for )]TJ
1.675 -1.25 Td
[(longitudinal observational studies in rheumatology)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1999;26:481-3.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR, Measurement of patient)]TJ
1.675 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Harrison BJ, Symmons DPM, Brennan P)110.7 (, et al. Inflammatory)]TJ
1.675 -1.25 Td
(polyarthritis in the community is not a benign disease: predicting)Tj
T*
(functional disability one year after presentation. J Rheumatol)Tj
0 Tc 0 Tw T*
(1996;23:1326-31.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (W)79.9 (ard MM, Leigh JP)110.7 (. Pooled time series regression analysis in)]TJ
1.675 -1.25 Td
(longitudinal studies. J Epidemiol 1993;46:645-58.)Tj
31.325 31.921 Td
[(7.)-875.1 (Matthews JNS, )54.8 (Altman DG, Campbell MJ, Royston P)110.8 (.)-0.1 ( )54.8 (Analysis of)]TJ
1.675 -1.25 Td
(serial measurements in medical research. BMJ 1990;300:230-5.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Bull SB. Regression models for multiple outcomes in lar)17.7 (ge)]TJ
1.675 -1.25 Td
(epidemiologic studies. Stat Med 1998;17:2179-97.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (W)39.8 (iles N, Dunn G, Barrett E, Silman )54.8 (A, Symmons D. )54.8 (Association)]TJ
1.675 -1.25 Td
(between demographic and disease related variables and disability)Tj
T*
(over the first five years of inflammatory polyarthritis: a )Tj
T*
(longitudinal analysis using generalised estimating equations. J Clin)Tj
T*
(Epidemiol 200;53:988-96.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Bukhari M, Harrison B, Lunt M, Scott DGI, Symmons DPM. )17.7 (T)35 (ime)]TJ
2.175 -1.25 Td
(to first occurrence of erosions in inflammatory polyarthritis.)Tj
T*
(Arthritis Rheum 2001;44:1248-53.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (D\325Agostino RBJ. Propensity score methods for bias reduction in the)]TJ
2.1381 -1.25 Td
(comparison of a treatment to a non-randomized control group. Stat)Tj
0 Tc T*
(Med 1998;17:2265-81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (W)39.8 (iles NJ, Lunt M, Barrett EM, et al. Reduced disability at five)]TJ
2.175 -1.25 Td
(years with early treatment of inflammatory polyarthritis: results)Tj
T*
[(from a lar)17.7 (ge observational cohort using propensity models to adjust)]TJ
T*
[(for disease severity)64.8 (. )54.8 (Arthritis Rheum 2001;44:1033-42.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Bukhari MAS, )17.7 (W)39.9 (iles NJ, Lunt M, et al. Influence of disease)]TJ
2.175 -1.25 Td
(modifying therapy on radiographic outcome in inflammatory)Tj
T*
[(polyarthritis at 5 years: results from a lar)17.7 (ge observational inception)]TJ
T*
[(study)64.9 (. )54.8 (Arthritis Rheum 2003;48:46-53.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>stream
8;Z\5!HQ(3#ikq,j?'ua8B?gt`*R=en'J3(P%"QOT^INN8&5le&T4d+Nu.e:mnY&K
rcm%!L:ka"I`fo6L-X6tO\:_BcaZ2XieA#l%pD)^UZ2KXjYn][E>YNVjH:S?ZD^a]
fOinqQ&ZJm7+)pA?*$+[ZcM8Lc$H7k)#NOH(b)q.7TL*<(8n]?QTrA9Bk<`\DAbQ-
Nfj);!O'C]FVIK#F2j06U6T"D^'f?Wr3UP9X/!(')$G8&Q]o#B_`.e0kUC!EG:o7Z
Fs32@*eYi@HhC0
endstream
endobj
40 0 obj
[/Indexed/DeviceRGB 255 39 0 R]
endobj
39 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
94 0 obj
<>
endobj
59 0 obj
<>
endobj
64 0 obj
<>
endobj
62 0 obj
<>
endobj
83 0 obj
<>
endobj
110 0 obj
<>
endobj
63 0 obj
<>
endobj
78 0 obj
<>stream
H|T PgQAizH@EeЀ<"s130QIU<q4`VCG*cTRIej^}]1Sqwz8~Fm\f"a1X6Ehrry"ی-[ nN+1#q\XteZ]ZzDHLDwq;JRlJ'՚HmNrV(cczEJJH*zE"1!OMx?dIW
66';kkX }OT;ɡ;XMI2 Z/j1+̅9?OuzdiX,m:n\kYk<̖HzN:ĺCj/U*
13TCyC~-VTY\AWA~F<7zYue%"m¼F#0\(TAvs=SZ)-0xÄPa1b
J:.ZD9K&O|^zTz.cMGdCbi:{8qw А.uCS3Y[9/ 'V0%}uH[TeU9lޡdEY;7b=1\ATR f3q>C˥h$<$GB=
#KOIm{
!O)rفH6+-ϲgN5H^p0hZXa ~Laڸr]mm:]y\0X6@X
G_kHrlZ^3~Ad@y
O"gOBX"8#xAw^ZNymA!ȖBDFgB3Ҕ{Y)(dhrDߞ-spq-tͮBrm92`(g/.z.}t@K -&oɞtnrvW!_bC=mz+bntCF뮷qr楗"k`L;e);w%o{H:N/ûi֖һ3a#d
A?Y9>;n6
]@%$]
|B}2K2!e8
2s
[pފ\s<~2MJ<`QlcdyUņ3E6
C7Lpǖ1(L#`wLM
۩U'Alc5jn4O\ƿ˞z/9$GW8G#L8%G!{ B"SbC]aq h7ߡ!B7ytuD*?*ױpc鏮WkB}K6nk+X:Ps _q[tf_VNJN 'jSs̾~8`ТYk?fUt~mƤh]<OyT r\_ϛ"d~|0GvaHc';7xfBҟ4JBhb*kX1DWxWÌ{Ad`p2yqysxn 5sF(H81IPxrcrlT.EugiQqQE{WKrӚsc@ΐ(ConIY8oCRK,@8
٣ AxdxpK oz@c|K$)hҲX'Pe
)}CY,=]mH=yz
f7>$SA#چC]QQ]WqUbanV"o@-*((! a"#.{x ""BS*1]}ƶgƸH4ff:;wZzm#n`
E@8=WjU0 m@, j8V}ƄGMdK!9I?z&n?5ԃ
2KH1)dD?@N,۴2*F?-O^¢>+ 왯/)q:8A/\+G{298=\1z4,AA0Zmx5Fo,%:9H˙8.+%wQymU #pOw&_qhY?Zq6Mh.`~/撺jL%sGš##
gqBrsae/Z?ŕh#b@j%$gLTUЁމaeX
Ҝ !m Yr,9Gw&0xcYsJٱo"$"?)JW`C
ңY]V{33EGpC\ƽ+G`3|:8:XЗjˣVɔ'5e;0WC IAKޕ$_L:Dbp8mhnˮ*T7j
G/K^7V0xp4
4
+ov."UZ-bAxbP)AfT"S\I'kT3㤣wbd3֨z'hb^ %A[X;
V`+>3yi]8